HPV

How to get vaccines to remote areas? In Sierra Leone they’re delivered by foot, boat or motorbike

Retrieved on: 
星期四, 四月 18, 2024
World Health Organization, Chlorine, Farm, Sanitation, Social Science Research Council, Motorcycle, International Growth Centre, COVID-19, Tablet, Vitamin A, Child, Death, Mercury, Telephone numbers in Hungary, Demographics of Sierra Leone, HPV, Vaccination, Safety, Science policy, Vaccine, Ministry, Pandemic, Nursing, Drinking water

In Sierra Leone almost 59% of the population live in remote, rural areas.

Key Points: 
  • In Sierra Leone almost 59% of the population live in remote, rural areas.
  • Roads may be non-existent or in bad condition, making it very difficult for rural dwellers to access healthcare.

Why are vaccination rates low in Sierra Leone?

  • In stark contrast, only 15% of people had been vaccinated in low-income countries.
  • The hardships Sierra Leoneans face are typical of the obstacles people in low-income countries have to overcome to access healthcare.
  • In the early days of the COVID-19 vaccination campaign in Sierra Leone, it took the average Sierra Leonean living in a rural community three-and-a-half hours each way to the nearest vaccination centre.

How did this vaccine drive tackle the problem?

  • The primary aim of this intervention was to take vaccine doses and nurses to administer vaccines to remote, rural communities, preceded by seeking permission and community mobilisation.
  • At the time, only 6% to 9% of the adults who took part in the programme were already immunised.
  • The leaders were asked for their cooperation in encouraging eligible community members to take the COVID-19 vaccine.
  • Finally, vaccine doses and healthcare workers arrived at the villages to administer the doses.

Looking forward

  • This approach proved 76% more cost-effective than other vaccination campaigns.
  • Transport accounted for a large share of the costs, so the cost-effectiveness of last mile delivery can be increased by offering a “bundle” of health products.
  • Other estimates put the death toll for the same period at 14.83 million, which is 2.74 times higher.
  • Developing cost-effective strategies to make vaccines easily accessible to everyone, everywhere, is the most promising solution to prevent future pandemics.


Niccolò Francesco Meriggi receives funding from Weiss Asset Management, UKRI and the International Growth Centre.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on: 
星期二, 四月 9, 2024
CPI, CPS, Disease, HNSCC, Patient, SAN, Inflammation, Pembrolizumab, HPV, AACR, CCR4, Therapy, PD-L1, Safety, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) --  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points: 
  • The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
  • The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
  • Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
  • In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.

LifeLabs Unveils At Home Kit Program, Empowering Ontarians to Prioritize Health with Ease

Retrieved on: 
星期二, 三月 26, 2024
Health, Kit, Human papillomavirus infection, Business, Cervical cancer, Patient, Canada Post, SVP, Commercial, MD, HPV, HPV16, Privacy, Collection, Consumer, Birth control

LifeLabs’ At Home Kit Program provides a diverse range of self-collection kits for various health tests, including cervical to colorectal health, hormonal health, and blood sugar monitoring.

Key Points: 
  • LifeLabs’ At Home Kit Program provides a diverse range of self-collection kits for various health tests, including cervical to colorectal health, hormonal health, and blood sugar monitoring.
  • This proactive and private solution caters to individuals with busy schedules, those facing accessibility challenges, and anyone prioritizing their wellness journey.
  • “Our mission at LifeLabs is to empower individuals to achieve optimal health by facilitating access to essential medical testing and supporting healthy lifestyle habits,” said Charles Brown, President and CEO of LifeLabs.
  • “The Cervical Health (HPV) Kit provides remarkable convenience for those who prioritize regular testing.

Prevent Cancer Foundation to visit Comadre a Comadre in Albuquerque

Retrieved on: 
星期五, 三月 22, 2024
Health, Education, Cervical cancer, Patient, Lung, NCI-designated Cancer Center, UNM, University, Breast, Cancer, Doctor of Philosophy, Compadre, Woman, HPV, Survivor, Yoli, Breast cancer, Vaccination, Liver, Skin, Birth control

Alexandria, Va., March 22, 2024 (GLOBE NEWSWIRE) -- On March 25, representatives of the Prevent Cancer Foundation® and its Congressional Families® Program will visit Comadre a Comadre, recipient of a $25,000 grant providing breast cancer education and navigation to Hispanic/Latina women across New Mexico.

Key Points: 
  • Alexandria, Va., March 22, 2024 (GLOBE NEWSWIRE) -- On March 25, representatives of the Prevent Cancer Foundation® and its Congressional Families® Program will visit Comadre a Comadre, recipient of a $25,000 grant providing breast cancer education and navigation to Hispanic/Latina women across New Mexico.
  • Lisa McGovern, Executive Director of the Congressional Families Program, and Erica Childs-Warner, Managing Director, Research, Education and Outreach, will represent the Prevent Cancer Foundation, joined by Rep. Teresa Leger Fernández (NM-03).
  • They deserve and have earned this national recognition and $25,000 grant from the Prevent Cancer Foundation to continue providing essential services for Latinas in New Mexico.
  • The Prevent Cancer Foundation is proud to support Comadre a Comadre in their work to reach this community and improve access to lifesaving screenings.

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
星期三, 三月 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

Infectious Disease Diagnostics Research Revolution 2024: New Report Analyzes OTC and DTC Trends and Strategies Through 2027 - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 5, 2024
Health, Infectious Diseases, TB, Collection, Disease, HPV, PerkinElmer, Pharmaceutical industry

5.2.2 Infectious Disease is Declining But..

Key Points: 

5.2.2 Infectious Disease is Declining But..
5.3.7 Sample Collection - Who Knew?
6.3 Co-Diagnostics Awarded $2.3M for TB, HPV Tests
6.32 Biohacking trend supports self-testing.
6.33 PerkinElmer and EverlyWell to Expand U.S. At-Home Health Test Market

Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024

Retrieved on: 
星期四, 三月 14, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, ASCC, DART, Head, Disease, Associate, Patient, Oropharyngeal cancer, DNA, Anal cancer, University, Management, Cancer, MD, Pembrolizumab, HPV, SRL Diagnostics, OPC, Medicare, Recurrence, Radiation therapy, Huntsman Cancer Institute, Pharmaceutical industry

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024 , taking place in Stockholm on March 13-16.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024 , taking place in Stockholm on March 13-16.
  • The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease.
  • Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications, leading to recent positive Medicare and commercial insurance coverage policies.
  • The study involved 150 patients, with NavDx tested pre-treatment and every three months post-treatment and patients followed for five years.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
星期三, 三月 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
星期二, 三月 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results

Retrieved on: 
星期四, 三月 14, 2024
PCR, Tuberculosis, COVID-19, Webcast, Research, EDT, Sale, Emergency Use Authorization, RSV, HPV, TB, FDA, Pharmaceutical industry

SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.

Key Points: 
  • SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.
  • Full Year 2023 Financial Results:
    Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests.
  • Co-Diagnostics plans to continue the development of our TB, multiplex respiratory, and HPV tests throughout the year," said Brian Brown, Co-Diagnostics' Chief Financial Officer.
  • Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.